Advanced search
Start date
Betweenand

An in vitro and in vivo antitumor mechanism of action evaluation of goniothalamin and its derivative, 2,4-dimethoxy-goniothalamin, in human breast cancer cells

Grant number: 14/26033-5
Support type:Scholarships abroad - Research Internship - Post-doctor
Effective date (Start): April 01, 2015
Effective date (End): March 31, 2016
Field of knowledge:Biological Sciences - Pharmacology
Principal Investigator:João Ernesto de Carvalho
Grantee:Ana Paula Oliveira Hohne
Supervisor abroad: Atanasio Pandiella Alonso
Home Institution: Centro Pluridisciplinar de Pesquisas Químicas, Biológicas e Agrícolas (CPQBA). Universidade Estadual de Campinas (UNICAMP). Paulínia , SP, Brazil
Local de pesquisa : Universidad de Salamanca (USAL), Spain  
Associated to the scholarship:13/15946-7 - Mechanism of antitumoral action of goniothalamin di-metoxy derivative and its mutagenicity and genotoxicity evaluation, BP.PD

Abstract

The dimethoxylated derivative of goniothalamin (diOMe-GTN), the target of the post-doctoral study of the candidate (FAPESP 2013/15946-7), showed promising in vitro antiproliferative activity for various tumor cell lines, in particular to those derived from human breast cancer MCF-7, MDA-MB-231 and MCF-7/BUS cells. Its effect on the cell cycle, as well as on the mechanism of cell death, on the proliferation of the cells under stimuli of hormones and its effects on the cell migration has been investigated and the results point to a pronounced antitumor activity. In order to continue the evaluation of its antitumor mechanism of action, we propose to evaluate its, and also goniothalamin, effect in human breast cancer (MCF-7) xenograft tumor model in rodents and also to investigate their effect in an in vitro resistance model with HER2-positive breast cancer (BT474 and SKBR3) cells. This evaluation will take genomic and proteomic approaches that should provide crucial information about the biological activity of GTN and diOMe-GTN, since, to the present time, there is just few information about their activities in breast cancer cells, and to identify the mechanisms by which these molecules act. This work has as partners Dr. Atanasio Pandiella, which has extensive experience in studies in breast cancer and animal testing, and the Centro de Investigación del Cáncer of the University of Salamanca (CSIC), Spain. (AU)

Distribution map of accesses to this page
Click here to view the access summary to this page.